Building 7
Kiryat Atidim
Tel Aviv 6158002
Israel
972 77 331 0156
https://www.chemomab.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director | 330k | N/A | 1982 |
Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer | 322k | N/A | 1971 |
Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development | 850k | N/A | 1969 |
Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | N/A | N/A | N/A |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.